H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)'s PKP2 Program [Yahoo! Finance]
Lexeo Therapeutics, Inc. (LXEO)
Company Research
Source: Yahoo! Finance
TheFly reported on January 13 that H.C. Wainwright analyst Mitchell Kapoor lowered the price target for LXEO to $10 from $13 and maintained a Buy rating. The firm believes that the market is still not persuaded by LXEO's recent PKP2 findings; the drop implies a lesser possibility of acceptance for the PKP2 program. A day earlier, on January 12, Lexeo Therapeutics, Inc. (NASDAQ:LXEO) released preliminary results from its HEROIC-PKP2 Phase I/II trial of LX2020, which is an AAV-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy. There was no clinically significant complement activation, and LX2020 was usually well tolerated across dosage cohorts. PKP2 protein increased in a dose-dependent manner during treatment, averaging 93% in the low-dose group and 162% in the high-dose group. Premature ventricular contractions and non-sustained ventricular tachycardia are examples of arrhythmia features that often improve or stabilize. Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is
Show less
Read more
Impact Snapshot
Event Time:
LXEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LXEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LXEO alerts
High impacting Lexeo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LXEO
News
- Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA TherapeuticsGlobeNewswire
- Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $17.00 price target on the stock.MarketBeat
- Lexeo Therapeutics (NASDAQ:LXEO) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy [Yahoo! Finance]Yahoo! Finance
- Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic CardiomyopathyGlobeNewswire
LXEO
Earnings
- 8/14/25 - Beat
LXEO
Sec Filings
- 1/30/26 - Form SCHEDULE
- 1/29/26 - Form SCHEDULE
- 1/27/26 - Form 8-K
- LXEO's page on the SEC website